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This service evaluation aimed to appraise the delivery of a fertility preservation service for 
women with cancer as part of an Assisted Conception Unit (ACU) in 2005. Firstly, the ACU-
database was interrogated between 08/2005 and 01/2017; revealing 174 women received 
referrals over the 12-year period with a steady referral increase each year. Demographic 
analyses revealed factors, such as being partnered, to be strong indicators of whether women 
would seek FP or not. To improve service provision, women who had consented to be contacted 
for research, received questionnaires to ascertain their perspectives on the FP-decision-making 
process, outcomes and ACU after-care. The majority perceived their experience as excellent 
due to the care they received from ACU staff, speed and efficiency in service delivery. The 
increasing number of referrals since 2005 is reassuring. This audit also highlighted 
shortcomings of the service, such as limited awareness of the fertility counselling service and 








What is already known on this subject? 
There has been an increase in women diagnosed with cancer undergoing fertility preservation 
(FP) before starting potential gonadotoxic treatment. Offering FP to these women is essential 
as the ability to have future children is often perceived as equally as important as survivorship, 
and a source of hope for the future. 
What do the results of this study add? 
This study presents a service evaluation, across a 12-year period, of delivering FP services to 
women with cancer in one UK Assisted Conception Unit (ACU). Women’s experiences of the 
service were evaluated to enhance service delivery and make recommendations for clinical 
practice.  
What are the implications of these findings for clinical practice and/or future research? 
The current service evaluation demonstrated increased rates of FP referral over a 12-year 




period for women with cancer. While this increasing number is reassuring and reflecting 
increased awareness among professionals and patients; shortcomings in the care pathway were 
also found: women reported limited opportunity to see fertility counsellors and desired better 
after care. This information may also be of benefit to other ACUs seeking to enhance and 









Approximately 11,000 women of reproductive age are diagnosed with cancer in the UK 
each year (The Royal College of Physicians Royal College of Radiologists and Royal College 
of Obstetricians and Gynaecologists, 2007). Many of these women will be exposed to 
gonadotoxic cancer treatment and be at increased risk of premature ovarian failure and 
infertility. Fertility preservation (FP) methods are available to those patients wishing to 
preserve their future fertility potential. 
The Human Fertilisation & Embryology Authority (HEFA) is an independent regulator 
of fertility treatment within the UK  (HEFA, 2018a). Through regular inspections of research 
centers and fertility clinics it ensures government safety standards and ethical rules are met 
(HEFA, 2018d). The HFEA has been collecting data from all UK-licensed fertility clinics on 
their performed treatment cycles and their outcomes since 1991 which is held on the HFEA 
register database (HEFA, 2018c). In their latest report in 2014, the HFEA listed 82 licensed 
fertility clinics offering IVF, with 52,288 women using the service and undergoing a total of 
67,708 cycles (HEFA, 2016). This is a 4.8% increase on the number of IVF cycles from 2013, 
with the majority of women receiving IVF aged below 37 (the average age being 35 years). 
This increase is a consequence of both increased demand from women seeking freezing 
for social reasons, such as career or relationship status (Von Wolff, 2015) but also medical 
reasons; in particular women diagnosed with cancer (Peate et al., 2009). As well as offering 
female cancer patients the opportunity to have potential biological offspring in the future; 
crucially, undergoing FP offers female cancer patients hope for a future after their cancer 
treatment (Tschudin and Bitzer, 2009; Vogt et al., 2018).  
NICE guidelines state that all newly diagnosed patients with cancer must be made 
aware of the potential gonadotoxic effects of their treatment before commencement, and be 
offered alternative treatment options that could cause a lower degree of gonadal damage 
(National Institute for Health and Clinical Excellence, 2013). Factors, such as cancer type, 
proposed treatment regimen, patient age and relationship status, need to be considered when 
discussing and undergoing fertility preservation (Kim et al., 2016). Currently, several well-
established FP strategies exist for women concerned over their future reproductive capacity 
due to potentially gonadotoxic medical treatments. These include mature oocyte and embryo 
cryopreservation, ovarian tissue cryopreservation and ovarian transposition and shielding (De 
Vos, Smitz and Woodruff, 2014). Despite the accomplishment of live births through ovarian 
tissue cryopreservation, this is still considered to be an experimental method, and thus 




somewhat controversial, with techniques for transplantation still evolving (Donnez and 
Dolmans, 2013; Oktay et al., 2016, 2018). Another potential fertility preserving method 
involves the use of gonadotrophin-releasing hormone (GnRH) analogues to suppress ovarian 
function during treatment. The evidence however, regarding the effectiveness of this technique 
is currently insufficient (Donnez and Dolmans, 2013).  
We aimed to evaluate in depth the clinical data gathered over the last 12 years of 
delivering such a fertility preservation service for women with cancer in one tertiary referral 
center. Women’s perceptions of using this service was also explored. It was hoped this 
information would enable us to i) understand in more detail the demographics of the women 
who access this service, ii) identify the support needs of women accessing the service, and 
identify ways that the fertility preservation service could be improved. 
Methods 
Materials 
Medical records. ACU patient records were screened by SM to identify all women with 
a diagnosis of cancer who were offered a referral and allocated an appointment to discuss FP 
at the unit during the period August 2005 to January 2017. Patients were included regardless 
of whether they attended the unit or not and if FP treatment was subsequently undertaken. 
Medical records were retrieved from either the ACU’s database or as paper notes.  
 
Questionnaire. A study-specific questionnaire was developed. This was based upon a review 
of the existing literature, and the involvement of two medical students who were undertaking 
their Intercalated BMedSci at the Unit (SMD, AW), the clinical lead for the ACU (JS), who 
has many years of experience working within the service and a health psychologist (GJ). The 
questionnaire covered eight key topics (referral process, consent process, menstruation and 
fertility, the counselling service, use of eggs/embryos, cancer treatment, current situation, 
contact with the clinic, overall experience). Eight open-ended questions were added to 
provide participants with the opportunity to express their answers in greater detail 
(Supplementary file 1). 
Procedure 




University of Sheffield ethics approval and Trust audit department approval for the 
evaluation of the service was also obtained. Medical records were entered into an SPSS 
(Version 21) database. No identifying information was recorded and all patients received a 
study-specific ID-number. 
Women, who had signed a HFEA ‘Disclosing Identifying Information’ form consenting 
to be contacted for research, were sent study packs in the post (February/March 2017). Study 
packs contained a cover letter, information sheet, study-questionnaire (with corresponding ID 
number) and a pre-paid return envelope. 
All statistical analysis was performed using SPSS version 22. Simple demographic 
data and participant responses were analysed using descriptive statistics, including Frequency 
and Valid Percentages (%). The continuous variables, age and number of oocytes collected, 
fertilised and stored were analysed using summary statistics, comprising mean, standard 
deviation and range. A Pearson Chi Square test was performed on the data to test if a 
significant difference existed in the proportion of women who had a partner or were single at 





One hundred and seventy-four women with cancer were offered and allocated an ACU 
referral over the 12-year period between 08/2005 and 01/2017. Figure 2 demonstrates the 
increase in referral rates; with the greatest number of referrals for the most recent year with 
complete data collection (2016). Seventeen different cancer diagnoses were identified; most 
commonly breast cancer (56.4%), followed by Hodgkin’s lymphoma (15.1%) and cervical 
cancer (6.4%). An overview of all cancer diagnoses is presented in Table 1. Mean age at the 
time of referral was 30.2 (SD 6.6; range 16 – 44).  
At time of referral, 114 (65.5%) women were married or partnered, 47 (27.0%) were 
single. Information regarding the relationship status of 13 women in this study was unavailable 
at the time of data collection; however, none of these subsequently pursued FP.  The 




relationship status of the rest was unknown. It was hypothesised that relationship status may 
have impacted upon the women’s decision making. A Pearson Chi Square test was performed 
X2 [(1, 148)  =  4.3 ], p=0.039; supporting this.  
Of the 174 referrals, three did not attend their appointment, 104 (59.8%) pursued FP 
treatment following ACU consultation, 67 did not pursue FP after attending their appointment. 
Seventeen were not offered treatment (gynaecological cancers, advanced disease, poor 
prognosis) while 50 decided against preservation (low chances of success, previous children, 
cost/funding concerns). These reasons were documented in patient files, i.e. had been 
documented by the health care professionals following the appointment. Notes for two women 
revealed more detail: one woman perceived the process as too overwhelming; another felt 
freezing embryos would go against her religious beliefs. However, the overriding concern for 
the majority of women was the risk associated with delaying cancer treatment.  
Of the 104 women, 58 (55.8%) froze embryos, 38 (36.5%) froze eggs and eight (7.7%) 
froze both. With the exception of one woman who used donor sperm, all the remaining women 
used sperm from their partner for embryos. One hundred (96.2%) women successfully 
managed to store at least one egg or embryo in their first cycle; four were unsuccessful (aged 
33, 34, 35, 42 years).  
The mean number of eggs collected in the 107 cycles performed was 10.2 (SD: 6.6, 
range: 0-39). Women who just froze oocytes, successfully froze a mean of 8.8 eggs (SD: 4.4, 
2-19). Those who froze embryos only, stored a mean of five (SD: 4.3; 0-26). Of the eggs 
collected, 62.6% were successfully fertilised and 93.1% of these were subsequently 
successfully frozen as embryos. Seven (4.5%) of the women who successfully stored eggs 
decided to destroy them post-treatment, most commonly due to a subsequent relationship 
breakdown. 
Of those having successfully frozen eggs/embryos, 18 (17.8%) were seen post-
treatment. Seven (5.9%) women have attempted to conceive using stored material; all had 
frozen embryos and were with partners. One used a surrogate. Overall, three live births were 
achieved. One woman was successful on her first cycle, another on her first cycle with a 
surrogate and the third woman had four cycles, with the first being unsuccessful, the next two 
resulting in a biological pregnancy (these were however terminated due to the foetus being 
diagnosed with cystic fibrosis) and the fourth cycle resulting in a pregnancy and live birth.  
The four other women who underwent treatment cycles themselves or via surrogates, 
used all of their embryos but were unable to achieve a live-birth.  








Out of the 174 women who received referrals to the ACU, 92 (52%) agreed to be 
contacted for service evaluation and research purposes. Ten patients were found to have 
deceased, resulting in 82 eligible patients. ACU staff recommended not to contact three patients 
due to personal circumstances. The remaining 79 were contacted, and 34 responded (43% 
response rate). Participants’ ages ranged from 19 to 47 years old (Mean: 33.5yrs; SD: 6.6). 
Twenty-four (70.6%) had a partner at time of referral and ten (29.4%) were single.  
Referral to ACU 
All were referred to the ACU due to a diagnosis of cancer between 2007-2017 (n=34, 
100%). Twenty-three (67.6%) women were offered a referral by their health care professional 
(HCPs) but nine requested it themselves. Five (14.7%) were seen within three days of referral, 
11 (32.4%) within a week, 13 (38.2%) within a month; only one woman waited longer than a 
month. Twenty-six (81.3%) women perceived this as quicker than expected or as expected. 
However, only 11 women (33%) felt they knew what would happen at their first consultation 
with the fertility expert.  
Decisions 
Twenty-eight (82.4%) women chose FP. Eighteen women (64.3%) indicated that they 
froze embryos, 8 (28.6%) eggs and two (7.1%) froze both. However, when merging the data 
on the existing SPSS file, it became apparent that one participant froze eggs rather than 
embryos.  
Fertility counselling service  
Only 12 (35.3%) women were aware of the fertility psychosocial counselling service, 
with 21 (61.8%) not being aware and one (2.9%) woman not sure. Twelve (35.3%) women 




were offered the opportunity to speak to a counsellor, compared to nine (26.5%) who weren’t 
and 13 (38.2%) who weren’t sure. Only five (16.1%) women saw a fertility counsellor. Those 
who have used the service, were either ‘Very Satisfied’ (n=2) or were ‘Satisfied’ (n=3). 
Informed decisions & consent  
Most were happy with the amount of time available to consider FP although one (3.8%) 
woman wished she had been given more time. Around 3/4 (70.4%) felt they fully understood 
the information, with twenty-five (92.6%) women feeling that they were given enough 
information to make an informed decision. All of the women felt that the consent process was 
explained by the appropriate person and 25 (92.6%) women felt that they fully understood what 
they were consenting to at the time.  
Post cancer-treatment 
Periods 
Initially, periods had stopped in 27 (84.4%) of the 34 women. They have since returned 
in 63.2% of patients. However, 41.7% still do not have regular cycles.  
Follow-up appointments 
Only nine (29%) women stated that they were offered follow-up appointments; 20 
(64.5%) were not, two (6.5%) did not know. At the time of completion, 25 (73.5%) had finished 
cancer treatment but only five had undergone blood tests to evaluate ovarian function.  
When asked if women would routinely like follow-up appointments to discuss fertility, 
the majority (62.5%) declared that they would. Among these, there were conflicting wishes as 
to how long after cancer treatment this should be which included 6 months post treatment 
completion, after 1 year, after two years, and when the woman feels ready. 
Outcomes & use of stored material 
Three women have since used their eggs/embryos. One used a surrogate (live birth, first 
cycle), one had one cycle herself resulting in a live birth and the third woman had four cycles 
which ultimately resulted in one live birth (one cycle unsuccessful, two terminations due to 




foetus being diagnosed with cystic fibrosis). All had frozen embryos. Sixteen of the remaining 
women who stored material, have thought about using them, three have not and five feel that 
it is not suitable for them at present (missing n=1).  
When asked if the women knew what to do about using stored material, fifteen (60%) 
said they would, seven (28%) said they wouldn’t know and three (12%) weren’t sure. Similarly, 
fourteen (56%) said that they would know who to talk to in order to use their eggs/embryos, 
seven (28%) said that they wouldn’t and four (16%) said that they didn’t know. One woman 
wrote: “If I can't conceive naturally, I shall be using them but I don't know how I would do 
this/who to contact”. (STH42). 
The majority (63.6%) of women have not been back in contact with the ACU since 
storing eggs/embryos. Twelve (36.4%) had been in contact to discuss using their eggs/embryos, 
check their fertility or ensure reception of storage letters. When asked whether they knew how 
to contact the clinic if they needed, 25 (78.1%) said they would, five (15.6%) said they 
wouldn’t and two (6.3%) said they don’t know (missing n=2).  
Women who had finished their cancer treatment were asked whether they had thought 
about trying to become pregnant since (n=25). Seven (36.8%) said they did not want a family 
yet, two (10.5%) had been advised not to have a pregnancy yet, three (15.8%) were currently 
trying, two (10.5%) had conceived naturally, two (10.5%) had conceived through fertility 
treatment and three (15.8%) did not know (missing n=6). For more than half the women, having 
children was still important for the future, for nine (31.0%) it was important at the moment, 
one (3.4%) not at the moment, two (6.9%) not at all and one (3.4%) did not know (missing 
n=5).  
Women were then given the option to express additional comments regarding their 
current situation and views on having children. A number of women noted the added 
complications that they now faced (e.g. not being able to bear a child anymore, trying to find a 
surrogate). A number of women also explained the impact of not being in a relationship and 
concerns for finding a donor. One woman wrote:  
“I do want children but am not in a relationship. Also, I cannot bear a child anymore 
(the radiotherapy made me sterile) so I have the added complication of finding a 
surrogate.” (STH01) 
 




Some women felt unsure whether becoming pregnant would be the right thing to do because 
of the chance of their cancer recurring.  
“Knowing the first five years are the 'danger periods' for my cancer returning, I feel 
that I need to get through this period without a relapse before I have children as it 
would be unfair to bring a child into the world not being in a long remission period. 
Once through this period, I will consider using my eggs if I am in a relationship or feel 
able to go it alone”. (STH25) 
 
A few women did want to start planning a family but were unsure how to go about this.  
“I am unable to conceive due to my treatment, I have eggs and embryos stored/frozen 
but I am unsure of my options if I wanted to use them/surrogate. The cost/legislation is 
confusing”. (STH29)  
 
Overall experience  
When asked to rate the FP service overall (scale: ‘Extremely poor’- ‘Excellent’), 14 
(43.8%) rated the service as ‘Excellent’, followed by ten (31.3%) ‘Very good’, four (12.5%) 
‘Good’, three (9.4%) ‘Neither good or bad’ and one (3.1%) ‘Extremely poor’ (missing n =2) 






It is now recognized as essential that, upon cancer diagnosis, women at risk of losing 
their fertility as a consequence of cancer treatment have the opportunity to discuss their FP 
options (Hoeg, Schmidt and Macklon, 2016). These discussions should be clearly documented 
in the patient’s medical records (Oktay et al., 2018). As a result, much recent literature focuses 
on women’s experiences of receiving fertility-related information around the time of diagnosis 
and their decision making at time of cancer diagnosis (e.g. Peate et al., 2009; Hershberger et 
al., 2012; Vogt et al., 2018). While this increase in research is encouraging, limited literature 
exists investigating the demographics of women who have had referrals to the ACU for FP, 
subsequently had cancer treatment and now have stored cryopreserved material.  




Furthermore, it is essential to evaluate the women’s experiences with the ACU service 
provision, their outcomes as well as experiences with the service in a retrospective manner in 
order to continually make improvements for patients.  
This service audit found a steady increase in women being offered, and seeking, FP 
referral since 2005, as demonstrated in Figure 2. Reasons for this may include increased 
awareness, both for patients and clinicians, advances in FP, more efficient referral pathways, 
enhanced information access and updated NICE guidelines (NICE, 2013). 
 
Being partnered was found to be a strong predictor for referral and the decision for 
undergoing FP; a finding which is supported in the literature (Gorman et al., 2012; Hershberger 
et al., 2012; Peddie et al., 2012; Mersereau et al., 2013; Corney and Swinglehurst, 2014; 
Corney, Puthussery and Swinglehurst, 2014). Single women commonly report feeling more 
vulnerable when pursuing FP without a partner to provide emotional and practical support; as 
well as anxieties about rejections from future partners (e.g. Corney and Swinglehurst, 2014). 
Relationship status however may also affect events post-treatment: for example, seven women 
decided to destroy their eggs or embryos since finishing treatment; the most common reason 
being break-down in the relationship with their FP partner. Thus, ensuring cancer patients are 
fully informed of the future ethical problems associated with freezing embryos, even if in a 
long-term committed relationship is therefore of utmost importance. Freezing both oocytes and 
embryos could mitigate these issues and allow greater flexibility for those who have a change 
in relationship-status after treatment. Other reasons reported against FP (age, funding, parity 
and not wanting to delay CT) are concurrent with those in the literature (e.g. Peate et al., 2009; 
G. Jones et al., 2017; Vogt et al., 2018). Women were generally satisfied with the ACU referral 
pathway. The majority were offered a referral without asking from their HCPs and felt that 
their referral was quicker than they expected; only one woman waited longer than a month. 
Over a quarter requested their own referrals, indicating knowledge of the potential impact of 
CT on fertility, as suggested above. 
The majority of women however have little prior knowledge of these effects, stressing 
the need for HCPs to initiate discussions on the topic (Crawshaw et al., 2009; Corney and 
Swinglehurst, 2014; Hoeg, Schmidt and Macklon, 2016). Therefore, information provision at 
time of referral is of utmost importance to empower women to make informed choices over 
their fertility - even if they do not subsequently opt to have FP (Lee et al., 2011).  




Women wishing to have FP must make an appointment to go through necessary 
information to sign consent forms (HEFA, 2018b). The majority of women from this service 
were content with this process, indicating enough time and information was available for 
informed decision-making. However, evidently, not all women fully understood what they 
were consenting to; one woman even reported the wrong outcome in her questionnaire. Two 
further women in this study expressed having to rush their FP decision due to their diagnosis 
and treatment. To ensure that supported and informed decisions are made which are not rushed, 
the service must therefore offer comprehensive consent procedures for its patients - despite 
limited time available.  
Results indicate that only seven women have attempted to conceive using their stored 
material; low return rates are also reported for other UK ACUs (Yap and Davies, 2007). A 
potential explanation is that not all women subsequently lose their fertility as a result of cancer 
treatment, but as ACUs are not routinely notified of natural births in women who previously 
underwent FP or whether their fertility was impaired post-treatment; this cannot be confirmed 
for this sample. On the other hand, low pregnancy rates in female cancer survivors are  
generally reported in the literature (Anderson et al., 2018); which may suggest that this low 
return rate maybe a consequence of the population itself. For example, women might be 
concerned about well-being or may be suffering emotional distress caused by the cancer 
diagnosis or treatment  making them less likely to use stored material. Additionally, it is also 
likely that some women - especially those with the more recent diagnoses – are not yet ready 
to get pregnant due to the suggested five-year observational period and wait between 
completion of treatment and pregnancy. Therefore, long-term studies and evaluation of 
individual cases is needed to shed more light into the return rates of fertility preservation in 
female cancer patients who have stored material in the ACU. 
After-care of FP patients has been judged as inadequate in a number of studies 
(Zebrack, Casillas and Nohr, 2004; Zebrack, 2008; Gorman et al., 2012). Patient’s unmet needs 
were similarly identified in the current study, with approximately half of women unsure how 
to go about using their stored material and not knowing who to talk to. Women expressed the 
additional dilemma they now face in deciding whether to use their stored material. Concerns 
included the chances of their cancer recurring, eligibility for funding, the need for a surrogate 
and the absence of a partner. Feeling overwhelmed by the associated cost (treatment cost, 
services, pursuing adoption/surrogacy) is concurrent with past research (Gorman et al., 2010). 




Elsewhere, women have also described thoughts of guilt and selfishness for desiring children 
when they may have a shorter life-span (Gonçalves, Sehovic and Quinn, 2014).  
Evidently, fertility epitomises a significant issue for most women in the study – both 
before and after cancer treatment- with 86% stating that having children at present or in the 
future is important. This is a common theme amongst cancer survivors (Tschudin and Bitzer, 
2009; Lee et al., 2011; Hill et al., 2012; Nilsson et al., 2014), with issues related to infertility 
negatively impacting on cancer survivors’ well-being and quality-of-life after cancer (Tschudin 
and Bitzer, 2009; Gonçalves, Sehovic and Quinn, 2014; Nilsson et al., 2014). A 2012 study 
(Gorman et al., 2012) reported that many women felt anxious and worried about whether they 
would be able to conceive in the future, but postponed seeking information about fertility due 
to fears of being told they were infertile. Unfortunately, cancer survivors often have a shorter 
fertility time-frame due to an earlier ovarian decline and therefore delaying fertility tests could 
hinder their chances of biological parenthood. In the present audit, less than 30% of women 
were offered a follow-up appointment, suggesting that many women could benefit from this 
service being offered and encouraged after cancer treatment. Worries about treatment-induced 
infertility have been shown to contribute to long-term symptoms of depression (Gorman et al., 
2010), reiterating the need for the service to improve the support it provides to its patients after 
their FP treatment has finished.  
 
Nonetheless, overall, around 50 % of patients in this audit perceived their experience 
at the ACU as excellent due to the care they received from staff, speed and efficiency in the 
service delivery. Suggestions for improvement from the participants included quicker referrals, 
superior knowledge of funding guidelines and increased after-care.  
Limitations of the study 
 
A number of study limitations arise. Due to the study spanning a 12-year period, women 
included in the study may have seen different ACU HCPs, which may have impacted on their 
experience. The retrospective nature of the study meant that some women used the service 
more than 10 years ago and may now be in remission or have given birth to a child, thus altering 
perspectives of their experiences. Perceptions may have also changed over time or some 
aspects may have been forgotten. The questionnaire had a response rate of 44.3 per cent. 




Therefore, it is uncertain as to what extent the responses are representative of the experiences 
of women who have used the service in general. Women who had a particularly negative or 
positive experience may have chosen to respond to the questionnaire, resulting in a potentially 
biased sample. The study did however have a diverse participant sample in terms of age, cancer 
diagnosis, relationship status and FP decision. Measures were used in an effort to increase the 
response rate (reminder letter, pre-paid envelope). Due to the study being conducted at one UK 
ACU, data may not be representative of women who have used a FP service at other UK 
centers. The results obtained however were very similar to those of other studies conducted in 
the UK.  
Another potential limitation of the current study is the fact that fertility preservation 
treatment has changed, and improved, drastically within the 12-year study period: it may 
explain the increase in number of referrals since 2005. Finally, data regarding patients’ 
endocrine function at follow-up would have been an important addition to the study but was 
not available at the point of data collection.  
 
Clinical Implications 
The first important clinical implication arises from characteristics of ACU referrals. 
The majority of women as expected (>50%) had breast cancer diagnoses, however there was a 
large range of other diagnoses. A retrospective study identified disparities in the referral 
practices of practitioners belonging to different oncology divisions, with women diagnosed 
with breast cancer or lymphoma more likely to receive a referral than women diagnosed with 
other malignancies (Bastings et al., 2014). These findings therefore stress the importance of 
attentiveness to FP across all cancer and non cancer specialties. 
Prior to their first ACU appointment, only 1/3 felt they knew what would happen once 
they arrived– a finding which is echoed in a similar questionnaire-based study (Hill et al., 
2012). HCPs who are involved in organising referrals, should therefore take time to prepare 
women for their ACU appointment by giving verbal or written information, or online-based 
resources, such as decision-aids (G. L. Jones et al., 2017).  
Once the ACU referral has taken place, it is critical that patients are offered the 
opportunity to see a fertility psychosocial counsellor who specialises in support and therapeutic 
counselling, due to the sensitive nature of decisions they are required to make. However, only 
35% of women at this ACU reported that they had been given the opportunity to speak to a 
fertility counsellor. Also, only 1/3rd of women indicated they were aware of this service at the 




time of FP with only five using the service; this is coherent with previous research reporting 
only few onco-fertility patients are offered this (Crawshaw et al., 2009; Hill et al., 2012; 
Corney and Swinglehurst, 2014; Goetsch, Volk and Woodruff, 2014). 
Despite FP offering much hope for future biological offspring and taking some 
concerns and emotional burdens off women with new diagnoses of cancer (Hoeg, Schmidt and 
Macklon, 2016), women also need to be informed that the chances for live births from FP are 
still relatively low. Fertility counselling therefore fulfills the purpose of providing the women 
with up-to date factual information, a crucial aspect of good clinical practice. As a result, the 
number of women offered FP need to be improved to ensure women are aware of all aspects 
of their decisions. This lack of supported decision making is concerning, and gives rise to 
(future) emotional conflict and miss-informed decisions; therefore, it is paramount that all 
women diagnosed with cancer receive ACU referral as well as fertility counselling service, in 
concordance with recommendations and guidelines from appropriate regulatory bodies. 
 
Conclusion 
In conclusion, our evaluation of the current service has demonstrated an increasing 
number of women referred to the ACU as a result of cancer diagnoses. The increasing number 
is reassuring, reflecting the recognized need for young female cancer patients to be given the 
chance to discuss FP and to give them the opportunity to have future biological offspring, if 
desired and providing diagnosis and prognosis allow. However, shortcomings in the care of 
these women were evident, especially around limited opportunity to see a fertility counsellor, 
lack of information provision to support women’s FP knowledge base and decision-making as 
well as better after care. These factors should be addressed in order to improve service 
provision for these women in the future.  
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Table 1: Women referred to the ACU: cancer diagnoses 
 
Cancer Type N (%) 
Breast  97 (56.4) 
Hodgkin’s Lymphoma 26 (15.1) 
Cervical 11 (6.4) 
Brain 8 (4.7) 
Ovarian 7 (4.1) 
Bowel Cancer 5 (2.9) 
Endometrial 4 (2.3) 
Acute Myeloid Leukaemia 3 (1.7) 
Non-Hodgkin’s Lymphoma 2 (1.2) 
Nasopharyngea 2 (1.2) 
Adrenal 1 (0.6) 
Melanoma 1 (0.6) 
Tonsil 1 (0.6) 
Chronic Myeloid Leukaemia 1 (0.6) 
Sarcoma 1 (0.6) 
Stomach 1 (0.6) 





Table 2: Service ratings 
 
Feedback score given Reasoning N 
(missing n=2) 
Excellent “from the receptionist to the 
embryologist, I was made 
totally at ease” (STH52)  
“all staff members were 
considerate and friendly, 
they appeared to go beyond 
what you might expect” 
(STH24). “very informative 
but empathetic, kind and 
supportive” (STH21) 
“caring, friendly, 
professional” (STH57)  
“all the staff were incredibly 
friendly and supportive to my 
situation. Being so young 
they tailored the care and 
service they gave me, which 
made me feel supported”. 
(STH10, aged 20) 
14 
Very good “excellent care at the unit but 
no after-care” (STH50) 
10 
Good “given the incorrect 
information regarding 
funding for a second round of 
treatment and this caused a 
lot of distress at the time” 
 “all doctors should know 
funding details necessary to 
give correct advice” (STH20 
4 
Neither good nor bad  3 
Poor?   
Extremely poor “People we had contact with 
did not listen so we lost all 
confidence in their ability to 
perform their medical tasks” 
(STH31).  
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